ARTICLE | Analyst Picks & Changes
Analyst picks & changes
June 21, 1993 7:00 AM UTC
Ligand Pharmaceuticals Inc. Denise Gilbert of Smith Barney, Harris Upham initiated coverage of LGNDA with a "venture" rating. Gilbert said the company's small molecule drugs, which interact with intracellular receptors, could impact an almost endless number of diseases, including cancer, cardiovascular disorders, gynecological disorders, inflammatory disorders and skin diseases. Clinical trials could begin in late 1993 for LGNDA's first two products: LG-1057 to treat acute ...